Brief: Instil Bio To Voluntary Pause Enrollment In Ongoing Clinical Trials Related To Manufacturing

Instil Bio

31/10/2022 11:24

Oct 31 (Reuters) - Instil Bio Inc  TIL.O :
    * INSTIL BIO ANNOUNCES VOLUNTARY PAUSE OF ENROLLMENT IN
ONGOING
CLINICAL TRIALS RELATED TO MANUFACTURING
    * INSTIL BIO - VOLUNTARILY PAUSED ENROLLMENT IN ITIL-168 &
ITIL-306 TRIALS PENDING OUTCOME OF MANUFACTURING ANALYSIS &
IMPLEMENTATION OF CORRECTIVE ACTIONS
    * INSTIL BIO INC - NO REGULATORY AGENCY, INCLUDING FDA, HAS
NOTIFIED COMPANY OF A CLINICAL HOLD IN ANY OF ITS CLINICAL
TRIALS
    * INSTIL BIO INC - OBSERVED DECREASED RATE OF SUCCESSFUL
MANUFACTURING OF ITIL-168 FOR PATIENTS RECENTLY ENROLLED IN
DELTA-1 TRIAL
    * INSTIL BIO INC - COMPANY INTENDS TO PROVIDE AN UPDATE ON
MANUFACTURING ANALYSIS BY EARLY Q1 2023
    * INSTIL BIO - CONFIRMS CASH RUNWAY INTO 2025 UPON
SUCCESSFUL
COMPLETION OF A POTENTIAL SALE-LEASEBACK TRANSACTION OF ITS
TARZANA MANUFACTURING FACILITY
    * INSTIL BIO - PRE-SPECIFIED SAFETY ANALYSIS IN DELTA-1
TRIAL BEEN
CONDUCTED ON PATIENTS WHO RECEIVED ITIL-168 & DID NOT IDENTIFY
UNEXPECTED SAFETY ISSUES
    * INSTIL BIO INC - COMMENCED AN END-TO-END ANALYSIS OF ITS
MANUFACTURING PROCESSES
    * INSTIL BIO - ON COMPLETION OF ANALYSIS OF MANUFACTURING
PROCESSES, PLANS TO TAKE CORRECTIVE ACTIONS TO IMPROVE RATE OF
MANUFACTURING SUCCESS & RESUME STUDY
    * INSTIL BIO INC - NO MANUFACTURING FAILURES HAVE BEEN
OBSERVED TO
DATE IN ONGOING PHASE 1 TRIAL OF ITIL-306

Source text for Eikon:  ID:nGNX9vvx35 
Further company coverage:  TIL.O 
 ((Reuters.Briefs@thomsonreuters.com;))